CAR-T cell therapy for Alzheimer’s?
A promising new area of Alzheimer’s research is borrowing a powerful tool from cancer medicine and the early results are turning heads.
CAR-T cell therapy, which involves engineering a patient’s immune cells to hunt down and destroy specific targets, has already transformed treatment for certain blood cancers like leukemia. Now, researchers are asking: what if we pointed those same engineered cells at the amyloid plaques that clog the brains of Alzheimer’s patients?
A recent study published in PNAS did exactly that. Scientists engineered a particular type of immune cell CD4+ T cells, known for their ability to regulate inflammation rather than simply destroy, to recognize and attack fibrillar amyloid-β, the sticky protein that accumulates in Alzheimer’s-affected brains. In mouse models, the results were encouraging: the CAR-T cells reduced amyloid deposits in the brain and, interestingly, appeared to recruit the body’s own immune cells to join the effort, reshaping the immune environment of the central nervous system in potentially beneficial ways.
This matters because current antibody-based Alzheimer’s treatments, the standard of care, carry real risks and offer only modest cognitive benefits. A cellular immunotherapy approach could sidestep some of those limitations.
That said, CAR-T therapy remains expensive and complex to manufacture, which has historically slowed its expansion beyond oncology. This research is still firmly in the proof-of-concept stage. But as a demonstration that the immune system can be precisely redirected to clear one of Alzheimer’s defining features, it opens an intriguing door, one that could eventually lead to a genuinely new class of treatment for the world’s most common cause of dementia.
This topic was featured in Great News podcast episode 37.
Source: Fight Aging!
